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tissues analysed including kidney and liver despite strong 
enhancement of sulfotransferase activity in both kidney 
and liver of hSULT1A1/2 mice relative to WT, kidney and 
liver being major organs involved in AA metabolism. In 
contrast, DNA adduct formation was strongly increased in 
hSULT1A1/2 mice compared to WT after treatment with 
3-nitrobenzanthrone (3-NBA), another carcinogenic aro-
matic nitro compound where human SULT1A1/2 is known 
to contribute to genotoxicity. We found no differences in 
AAI-/AAII-DNA adduct formation in Sult1a1(−/−) and 
WT mice in vivo. Using renal and hepatic cytosolic frac-
tions of hSULT1A1/2, Sult1a1(−/−) and WT mice, we 
investigated AAI-DNA adduct formation in vitro but failed 
to find a contribution of human SULT1A1/2 or murine 
Sult1a1 to AAI bioactivation. Our results indicate that 
sulfo-conjugation catalysed by human SULT1A1 does not 
play a role in the activation pathways of AAI and AAII 
in vivo, but is important in 3-NBA bioactivation.
Keywords Aristolochic acid nephropathy · 
Sulfotransferase 1A1 · Carcinogen metabolism · 
DNA adducts · Balkan endemic nephropathy · 
3-Nitrobenzanthrone
Introduction
Aristolochic acid (AA), the natural extract of Aristolochia 
plants consists of structurally related nitrophenanthrene 
carboxylic acids, the major components being aristolochic 
acid I (AAI) and aristolochic acid II (AAII) (Fig. 1a) (Arlt 
et al. 2002c). AA is found in all parts of plants of both the 
Aristolochia and Asarum genera of the family Aristolochi-
aceae. Aristolochia herbs have been used for remedies 
throughout the world since antiquity and they remain in use 
Abstract Exposure to aristolochic acid (AA) causes aris-
tolochic acid nephropathy (AAN) and Balkan endemic 
nephropathy (BEN). Conflicting results have been found 
for the role of human sulfotransferase 1A1 (SULT1A1) 
contributing to the metabolic activation of aristolochic acid 
I (AAI) in vitro. We evaluated the role of human SULT1A1 
in AA bioactivation in vivo after treatment of transgenic 
mice carrying a functional human SULT1A1-SULT1A2 
gene cluster (i.e. hSULT1A1/2 mice) and Sult1a1(−/−) 
mice with AAI and aristolochic acid II (AAII). Both com-
pounds formed characteristic DNA adducts in the intact 
mouse and in cytosolic incubations in vitro. However, we 
did not find differences in AAI-/AAII-DNA adduct lev-
els between hSULT1A1/2 and wild-type (WT) mice in all 
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today, particularly in Chinese herbal medicine (Schmeiser 
et al. 2009).
In the 1970s the anti-inflammatory properties of AA 
prompted the production of pharmaceutical preparations 
until it was shown that AA is a strong carcinogen in rats 
(Mengs et al. 1982). Subsequently, AA was found to be a 
genotoxic mutagen and all pharmaceutical preparations 
containing AA were withdrawn from the market first in 
Germany and later in many other countries. In 2012 AA 
was classified by the International Agency for Research 
on Cancer (IARC) as carcinogenic to humans (Group 1) 
acting by a genotoxic mechanism. Today there is compel-
ling evidence that human exposure to AA leads to chronic 
renal disease and upper urinary tract cancer known as aris-
tolochic acid nephropathy (AAN) (Nortier et al. 2000), 
which is now recognised as a global disease (Gokmen et al. 
2013).
The metabolism of AA has been studied in several 
species demonstrating that the major metabolites found 
in urine and faeces are the aristolactams I and II (Chan 
et al. 2006; Krumbiegel et al. 1987), produced by exhaus-
tive six-electron reduction of the nitro group. Other minor 
metabolites are formed through O-demethylation of AAI 
to 8-hydroxyaristolochic acid I (AAIa) and through deni-
tration. Further reduction of AAIa leads to aristolactam Ia. 
The only metabolites identified in humans so far are the 
aristolactams I and II found in urine (Krumbiegel et al. 
1987).
Many studies have shown that AAI and AAII are gener-
ally bioactivated by reduction of the nitro group (Fig. 1a) 
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Fig. 1  Proposed pathways of bioactivation and DNA adduct formation by AA (a) and 3-NBA (b). See text for details
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(Stiborova et al. 2013, 2014a). Several human enzymes 
capable of activating AA by nitroreduction have been iden-
tified and include cytosolic NAD(P)H:quinone oxidoreduc-
tase (NQO1) (Stiborova et al. 2002, 2003), and microsomal 
enzymes including cytochrome P450 (CYP) 1A1, CYP1A2 
and NADPH:CYP oxidoreductase (Arlt et al. 2011, 2015a; 
Stiborova et al. 2001a, 2005, 2012). It has been shown 
that both AAI and AAII exert their genotoxic and carcino-
genic properties by DNA adduct formation and that reduc-
tive metabolic activation is a prerequisite for generation 
of DNA adducts in vivo and in vitro (Gokmen et al. 2013; 
Schmeiser et al. 2009).
Deduced from the structures of the AA-DNA adducts 
characterised spectroscopically, we have proposed that a 
N-acylnitrenium ion with a delocalised positive charge is 
the ultimate carcinogen binding covalently to DNA and 
forming DNA adducts (Stiborova et al. 2014b). This pen-
tacyclic aristolactam cation ion is formed during partial 
reduction of the nitro group to the N-hydroxy derivative 
(N-hydroxyaristolactam) after condensation with the car-
boxylic acid moiety in the peri position is the direct pre-
cursor for binding to the exocyclic amino group of nucle-
obases via the C7 position (Fig. 1a). The major AA-DNA 
adducts have been identified as: 7-(deoxyadenosin-N6-yl)
aristolactam I (dA-AAI); 7-(deoxyguanosin-N2-yl)aristo-
lactam I (dG-AAI); 7-(deoxyadenosin-N6-yl)aristolactam 
II (dA-AAII); and 7-(deoxyguanosin-N2-yl)aristolactam II 
(dG-AAII) (Schmeiser et al. 2009, 2014). Characteristic AT 
to TA transversion mutations have been found in urothelial 
tumours of AAN patients highlighting the role of dA-AAI 
adducts as critical premutagenic lesions in AA malignancy 
(Arlt et al. 2007; Lord et al. 2004; Nik-Zainal et al. 2015; 
Poon et al. 2013).
The N-hydroxyaristolactams I and II have been detected 
in the urine of AA-treated rats (Chan et al. 2007) indicating 
that they are rather stable compounds. This was confirmed 
by the study of Sidorenko et al. (2014) which showed 
that both N-hydroxyaristolactams did not react with DNA 
in vitro at pH 5.8 in the presence or absence of zinc dust 
as a reducing agent. It is well known that conjugation reac-
tions catalysed by phase II enzymes are often involved in 
the activating metabolism of carcinogenic nitroaromat-
ics (Arlt et al. 2005; Glatt and Meinl 2004; Glatt et al. 
2016; Rendic and Guengerich 2012). Phase II metabo-
lites of AA have been found in the urine and faeces of 
AA-treated rodents and include the N- and O-glucuronide 
of aristolactam Ia and the O8-glucuronide, the O8-acetate 
and O8-sulfonated ester of AAIa (Chan et al. 2007); AAIa 
is considered to be a detoxification product (Levova et al. 
2011; Stiborova et al. 2012). As shown for other aromatic 
hydroxylamines (Glatt and Meinl 2004; Glatt et al. 2016), 
like those generated during the metabolism of 3-nitroben-
zanthrone (3-NBA) (Arlt et al. 2002b, 2003, 2005), the 
N-hydroxyaristolactams may be further activated by 
O-acetylation or O-sulfonation to reactive esters capable 
of generating the same electrophilic species (aristolac-
tam-nitrenium ions) as formed by direct cleavage of the 
hydroxyl group. However, such aristolactam-N-oxy-esters 
have not yet been identified in studies of the metabolism of 
AA, which may be owed to their high reactivity.
Some of us recently reported that phase II reactions do 
not play a role in the bioactivation of AAI; neither native 
enzymes present in human cytosol nor human recombi-
nant sulfotransferase (e.g. SULT1A enzymes) nor N,O-
acetyltransferases (NATs) enhanced AAI-DNA adduct 
levels in vitro (Stiborova et al. 2011). In contrast, Meinl 
et al. (2006) demonstrated that expression of human 
SULTs (mainly SULT1A1) increased the mutagenic activ-
ity of the natural mixture AA in bacterial and mamma-
lian cells. Moreover, Sidorenko et al. (2014) showed that 
O-sulfonated and O-acetylated N-hydroxyaristolactam I 
and II readily form DNA adducts in vitro and that binding 
of N-hydroxyaristolactam I and II to DNA was stimulated 
by mouse cytosol in the presence of 3′-phosphoadenosine-
5′-phosphosulfate (PAPS), the cofactor for SULT enzymes. 
Furthermore, analysis showed that human SULT1B1, 
SULT1A1 and SULT1A2 can stimulate DNA adduct for-
mation by N-hydroxyaristolactam I and II (Sidorenko et al. 
2014).
The primary aim of the present study was to evaluate 
the bioactivation of AAI and AAII mediated by human 
SULT1A1 in a transgenic mouse model. We employed 
a transgenic mouse line carrying the functional human 
SULT1A1-SULT1A2 gene cluster (Dobbernack et al. 2011). 
In addition, we used Sult1a1(−/−) and Sult1d1(−/−) 
mouse lines (Bendadani et al. 2014a; Herrmann et al. 
2014). DNA adduct formation in vivo and in vitro was 
investigated by the 32P-postlabelling method.
Materials and methods
Carcinogens
Aristolochic acid mixture was purchased from ACROS 
Organics (#226095000). 3-NBA (CAS number 17117-34-
9) was prepared as previously reported (Arlt et al. 2002b).
Isolation of AAI and AAII
AAI (CAS number 313-67-7) and AAII (CAS number 
475-80-9) were purified from the commercially available 
AA mixture by reverse phase chromatography. Injections 
(1 mL) of AA mixture, at 10 mg/mL concentration in ace-
tonitrile/25 mM triethylammonium acetate (TEA) mix, 
were made onto a Gemini column (10 μm, 250 × 21.2 mm, 
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C18, Phenomenex, USA). Chromatographic separation at 
room temperature was carried out using 322 HPLC pump 
(Gilson, USA) over a 15-min gradient elution from 25:75 
to 40:60 acetonitrile/25 mM TEA at a flow rate of 20 mL/
min. Collection was triggered by UV signal (acquired at 
254 nm) and collected using a Gilson GX-281 Liquid Han-
dler system (Gilson, USA). The resulting TEA salts of 
AAI and AAII were converted back to the free acids using 
HCl. Addition of molar equivalent of NaOH produced the 
sodium salts which were freeze-dried for use. The purity of 
AAI and AAII (as sodium salts) was checked using 1D and 
2D NMR and high-resolution mass spectrometry (HRMS) 
which confirmed the compound structures.
Mouse lines
Wild-type (WT) FVB/N mice (subsequently termed WT 
mice) were purchased from Harlan (Borchen, Germany). 
The generation of transgenic FVB/N mice with multiple 
copies of the human SULT1A1‒SULT1A2 gene cluster 
integrated in chromosome 9 has been described elsewhere 
(Dobbernack et al. 2011). The line termed tg1 in the origi-
nal study was used. The homozygous transgenic line was 
bred with WT mice to generate animals with a hemizy-
gous gene status with respect to the human transgene 
(subsequently termed hSULT1A1/2). Sult1a1(−/−) and 
Sult1d1(−/−) mice were constructed as described else-
where (Bendadani et al. 2014a; Herrmann et al. 2014).
Animal treatment
All animal experiments were conducted in accordance with 
the law at the German Institute of Human Nutrition (DIfE) 
Potsdam-Rehbrücke, Nuthetal, Germany, after approval by 
the Landesamt für Umwelt, Gesundheit und Verbrauch-
erschutz of the State of Brandenburg (reference 23-2347-
18-2009). Animals were maintained under timed lighting 
conditions. Food (Altromin C1000 pellets, Altromin, Ger-
many) and water were available ad libitum. Groups male 
mice (n = 4; 8–10 weeks of age) were used throughout the 
study. WT, hSULT1A1/2, Sult1a1(−/−) and Sult1d1(−/−) 
mice were treated with a single dose of 50 mg/kg body 
weight AAI or AAII by oral gavage according to treatment 
protocols used previously to study AA metabolism (Arlt 
et al. 2011; Levova et al. 2011; Stiborova et al. 2012). AAI 
and AAII (as sodium salts) were dissolved in water at a 
concentration of 5 mg/mL. Control mice received gavage 
of solvent (water) only. Similarly, WT and hSULT1A1/2 
mice were injected i.p. with a single dose of 2 mg/kg body 
weight of 3-NBA according to treatment protocols used 
previously to study 3-NBA metabolism (Arlt et al. 2005; 
Krais et al. 2016a; Kucab et al. 2016). 3-NBA was dis-
solved in tricaprylin at a concentration of 0.2 mg/mL. 
Control animals received solvent (tricaprylin) only. Ani-
mals were killed 24 h post-treatment, and their kidney, 
bladder, liver, lung, forestomach, glandular stomach, small 
intestine and colon were removed, snap-frozen in liquid 
nitrogen and stored at −80 °C until further analysis. DNA 
was isolated from tissue by a standard phenol–chloroform 
extraction method.
Detection of DNA adducts by 32P‑postlabelling
AAI- and AAII-DNA adduct formation was analysed by 
the nuclease P1 enrichment version of the 32P-postlabel-
ling method as described (Schmeiser et al. 1996, 2012). 
Resolution of 32P-labelled adducts was performed by pol-
yethyleneimine-cellulose (PEI) thin-layer chromatography 
(TLC) using the following chromatographic conditions: 
D1: 1 M sodium phosphate, pH 6.5; D3: 3.5 M lithium 
formate, 8.5 M urea, pH 4.0; D4: 0.8 M lithium chloride, 
0.5 M Tris–HCl, 8.5 M urea, pH 9.0; D5: 1.7 M sodium 
phosphate, pH 6.0. After chromatography, TLC plates were 
scanned using a Packard Instant Imager (Dowers Grove, IL, 
USA), and DNA adduct levels (RAL, relative adduct label-
ling) were calculated as described (Schmeiser et al. 2013). 
Results were expressed as DNA adducts/108 normal nucle-
otides. AA-DNA adducts were identified using reference 
compounds as described (Schmeiser et al. 1996). Urothe-
lial DNA samples from AAN patients were included in the 
analysis for comparison (Nortier et al. 2000; Schmeiser 
et al. 2014). For 3-NBA, the butanol-enrichment version 
of the 32P-postlabelling assay was performed to determine 
DNA adduct formation (Arlt et al. 2002b; Phillips and 
Arlt 2014). Chromatographic conditions for TLC were: 
D1: 1.0 M sodium phosphate, pH 6.0; D3: 4.0 M lithium 
formate, 7.0 M urea, pH 3.5; D4: 0.8 M lithium chloride, 
0.5 M Tris, 8.5 M urea, pH 8.0. Using Instant Imager tech-
nology, DNA adduct levels (i.e. RAL) were calculated 
as described (Arlt et al. 2002b) and expressed as DNA 
adducts/108 nucleotides. 3-NBA-derived DNA adducts 
were identified as reported (Arlt et al. 2001, 2006).
Expression of Sult1a1/SULT1A1 and Nqo1 by Western 
blotting
For the preparation of whole tissue protein, tissues 
(5–10 mg) of WT and hSULT1A1/2 mice treated with AAI 
and AAII were homogenised in 300 µL of T-PER™ buffer 
supplemented with 1 % Halt™ Protease Inhibitor (both 
from Thermo Scientific). Samples were sonicated and cen-
trifuged for 20 min at 13,000g at 4 °C. The supernatant 
was removed and protein concentration was determined 
using the Pierce® BCA protein assay kit (Thermo Scien-
tific, USA) according to manufacturer instructions. Protein 
samples (20 µg) were denatured with ß-mercaptoethanol 
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at 80 °C for 10 min prior to loading onto 10 % Bis–Tris 
26-well NuPAGE midi gels. Proteins were separated by 
sodium dodecyl sulfate–polyacrylamide electrophoresis 
(SDS-PAGE) in MOPS buffer at 130 V and subsequently 
transferred onto a nitrocellulose membrane at 100 V for 
2 h. The membrane was blocked in 3 % w/v non-fat milk 
dissolved in 0.2 % TBS-T (Tris-buffered saline contain-
ing 0.2 % Tween-20), then probed overnight at 4 °C with 
the following antibodies: Human SULT1A1 was detected 
with antisera raised in rabbits against bacterial inclu-
sion bodies of human SULT1A 1:10,000; (Martin et al. 
2010), mouse Nqo1 was detected with rabbit pAb #N5288 
(1:5000; Sigma). Peroxidase-conjugated goat anti-rabbit 
(#170-5046; 1:10,000; Bio-Rad) was used as secondary 
antibody. Gapdh was detected with mouse mAb #MAB374 
(1:10,000; Millipore) in 3 % milk at room temperature for 
1 h and peroxidase-conjugated goat anti-mouse as second-
ary anti-mouse (#170-5047; 1:10,000; Bio-Rad). All pro-
teins were visualised using enhanced chemiluminescence 
SuperSignal West Pico detection reagent (#34080; Thermo 
Scientific).
Preparation of cytosols
Hepatic and renal cytosols were isolated as described (Arlt 
et al. 2008, 2015b; Krais et al. 2016a, b). Because treat-
ing the mice with AAI or AAII might influence levels and 
activities of xenobiotic-metabolising enzymes (XMEs), 
cytosols were isolated from organs of both control (vehicle-
treated) and AAI-AAII-treated mice (see above). Pooled 
cytosolic fractions (n = 4 mice per group) were used for 
further analysis. Small aliquots were stored at −80 °C until 
use.
Cytosolic incubations used for AAI‑DNA adduct 
analysis
The de-aerated and nitrogen-purged incubation mixtures, in 
which cytosols were used to activate AAI, contained 50 mM 
Tris–HCl buffer (pH 7.4), 0.2 % Tween 20, cofactors 
for cytosolic enzymes Nqo1 and sulfotransferase (1 mM 
NADPH with or without 100 µM PAPS), 1 mg mouse 
hepatic or renal cytosolic protein, 0.5 mg calf thymus DNA 
(2 mM dNp) and 0.5 mM AAI in a final volume of 750 µL. 
Incubations with cytosols were performed at 37 °C for 
60 min; AAI-derived DNA adduct formation was found to 
be linear up to 2 h (Stiborova et al. 2003). Control incuba-
tions were performed either (1) without cytosol, (2) without 
cofactors (NADPH, PAPS), (3) without DNA or (4) without 
AAI. After extraction with ethyl acetate DNA was isolated 
from the residual water phase by a standard phenol/chloro-
form extraction method. AAI-DNA adduct formation was 
analysed by 32P-postlabelling as described above.
Determination of Nqo1 activity in cytosolic fractions
Nqo1 activity was measured in hepatic and renal cytosols 
using menadione (2-methyl-1,4-naphthoquinone) as a sub-
strate as described previously (Levova et al. 2011, 2012; 
Mizerovska et al. 2011). The assay was improved by the 
addition of cytochrome c and Nqo1 activity expressed as 
nmol cytochrome c reduced.
Determination of sulfotransferase activity in cytosolic 
fractions
Sulfotransferase enzyme activity was characterised in renal 
and hepatic cytosolic samples by monitoring the formation 
of p-nitrophenol from a 5′-phosphoadenosine 3′-phospho-
sulfate (PAPS)-regenerating system (Frame et al. 2000; 
Krais et al. 2016b). It is based on the catalysed synthesis 
of 2-naphthylsulphate from 2-naphthol and PAPS through 
sulfotransferase while PAPS is continuously regenerated 
by using p-nitrophenyl sulphate as sulfo-group donor. In a 
96-well plate the incubation mixture (200 µL per well) con-
tained 48 mM sodium phosphate buffer (pH 7.4), 20 µM 
PAPS, 5 mM p-nitrophenyl sulfate potassium salt, 0.1 mM 
2-naphthol, 1 mM MgCl2 and 400–600 µg protein of cyto-
solic fraction. Shortly before the measurement, the reaction 
was initiated by the addition of 2-naphthol. The colorimet-
ric formation of p-nitrophenol was detected by its absorb-
ance at 405 nm in kinetic manner every 2 min for 60 min 
on a Synergy HT Plate Reader (Bio-TEK Instruments). 
Enzyme activities were calculated as nmol p-nitrophenol 
per min/mg protein.
Cytosolic incubations used for 3‑NBA‑derived DNA 
adduct analysis
The de-aerated and nitrogen-purged incubation mixtures, in 
a final volume of 750 µL, consisted of 50 mM Tris–HCl 
buffer (pH 7.4), containing 0.2 % Tween 20, cofactors for 
cytosolic enzymes Nqo1 and Sult/SULT (1 mM NADPH 
with or without 100 µM PAPS), 1 mg of mouse hepatic 
cytosolic protein, 100 µM 3-NBA (dissolved in 7.5 µL 
dimethylsulfoxide [DMSO]) and 0.5 mg of calf thymus 
DNA. The reaction was initiated by adding 3-NBA. Incuba-
tions with human cytosols were carried out at 37 °C for 3 h; 
the cytosol-mediated 3-NBA-derived DNA adduct forma-
tion was found to be linear up to 4 h (Arlt et al. 2005). Con-
trol incubations were carried out (1) without activating sys-
tem (cytosol), (2) without cofactors (NADPH, PAPS), (3) 
without DNA or (4) without 3-NBA. After extraction with 
ethyl acetate, DNA was isolated from the residual water 
phase by phenol/chloroform extraction. 3-NBA-derived 
DNA adduct formation was analysed by 32P-postlabelling 
as described above.
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Statistical analysis
Statistical analyses were performed with Prism Graph-
Pad Software (version 6.04), and P < 0.05 was considered 
significant.
Results
DNA adduct formation in WT versus hSULT1A1/2 mice 
treated with AAI, AAII and 3‑NBA
AAI-/AAII-DNA adduct formation was determined by 
32P-postlabelling in kidney, bladder, liver, lung, forestom-
ach, glandular stomach, small intestine and colon of WT 
and hSULT1A1/2 mice treated with a single oral dose of 
50 mg/kg body weight AAI or AAII for 24 h. The adduct 
pattern induced by AAI and AAII were qualitatively similar 
in all organs of both mouse lines tested. The pattern induced 
by AAI consisted of two major adduct spots, identified 
previously (Arlt et al. 2002c) as 7-(deoxyadenosin-N6-yl)-
aristolactam I (dA-AAI) and 7-(deoxyguanosin-N2-yl)-
aristolactam I (dG-AAI) (see insert Fig. 2a). Similarly, after 
treatment with AAII two observed major adduct spots were 
identified (Arlt et al. 2002c) as 7-(deoxyadenosin-N6-yl)-
aristolactam II (dA-AAII) and 7-(deoxyguanosin-N2-yl)-
aristolactam II (dG-AAII) (see insert Fig. 2b). dA-AAI, 
dG-AAI and dA-AAII have been found in urothelial tissue 
of AAN patients (Arlt et al. 2002a; Bieler et al. 1997; Nor-
tier et al. 2000; Schmeiser et al. 2012). No DNA adducts 
were detected in control (vehicle-treated) animals (data not 
shown).
Total AAI-DNA adduct levels found in organs ranged 
from 25 to 2300 adducts per 108 nucleotides (Fig. 2a). 
Highest DNA binding was observed in the kidney where 
adduct levels were ~35-fold higher than in liver, fol-
lowed by forestomach and small intestine, but there were 
no significant differences between both mouse lines in 
DNA adduct formation in any of the tissues investigated 
(Fig. 2a). Similarly no differences in DNA binding between 
mouse lines were observed after AAII treatment (Fig. 2b). 
Again, total AAII-DNA adduct formation was the high-
est in the kidney (~1300 adducts per 108 nucleotides) with 
adduct levels being much lower in all other tissues. It is 
noteworthy that AAI-DNA adduct levels in forestomach 
and small intestine were much higher compared to levels of 
DNA adduct induced by AAII in these tissues. Collectively, 
these findings indicate that expression of human SULT1A 
does not contribute to the bioactivation of AAI and AAII 
in vivo.
As 3-NBA is activated by SULTs (Arlt et al. 2002b, 
2003, 2005), 3-NBA-DNA adduct formation in the 
same mouse lines was measured by 32P-postlabelling 
in kidney, bladder, liver, lung, forestomach, glandular 
stomach, small intestine and colon after 3-NBA treat-
ment with a single i.p. dose of 2 mg/kg body weight for 
24 h. We have shown previously that metabolic activa-
tion of 3-NBA occurs after initial nitroreduction cata-
lysed by cytosolic nitroreductases (e.g. NQO1) leading 
to N-hydroxy-3-aminobenzanthrone (N–OH-3-ABA) 
(Fig. 1b) (Arlt 2005). The genotoxicity (i.e. DNA adduct 
formation) of N–OH-3-ABA is enhanced by the expres-
sion of SULT1A1 or SULT1A2 in bacterial and mamma-
lian cells in culture (Arlt et al. 2002b, 2003, 2005). Previ-
ous studies have also shown that enrichment by butanol 
extraction yields more adduct spots and a better recovery 
of 3-NBA-DNA adducts than using enrichment by nucle-
ase P1 digestion (Arlt et al. 2001). The adduct pattern 
induced by 3-NBA consisted of a cluster of four major 
adducts (spots 1‒4) in all tissues tested (see insert Fig. 3). 
These were characterised previously as 2-(2′-deoxyaden-
osin-N6-yl)-3-aminobenzanthrone (dA-N6-3-ABA; spot 
1), 2-(2′-deoxyguanosin-N2-yl)-3-aminobenzanthrone 
(dG-N2-3-ABA; spot 3) and N-(2′-deoxyguanosin-8-
yl)-3-aminobenzanthrone (dG-C8-N-3-ABA); spot 4), 
while spot 2 is an as-yet-uncharacterised deoxyadenosine 
adduct (Arlt et al. 2001, 2006). No DNA adducts were 
observed in DNA isolated from tissue of control animals 
treated with vehicle only (tricaprylin) (data not shown).
Except for the liver, compared to WT mice DNA binding 
by 3-NBA was up to ~fivefold higher in kidney, bladder, 
lung, forestomach, glandular stomach, small intestine and 
colon of hSULT1A1/2 mice (Fig. 3). These findings demon-
strate that the expression of human SULT1A increases the 
activation of 3-NBA in several organs in vivo.
Organ‑specific expression of human SULT1A1/2 
and mouse Nqo1 proteins in WT and hSULT1A1/2 mice 
treated with AAI and AAII
In order to verify the expression of human SULT1A1/2 pro-
teins in the hSULT1A1/2 mice treated with AAI and AAII 
we used Western blotting (Fig. 4). Immunoblotting using 
anti-hSULT1A antisera that cross-reacted only marginally 
with murine Sult1a proteins was performed in colon, small 
intestine, glandular stomach, kidney, liver and lung. No tis-
sue for analysis was left from forestomach and bladder as 
the whole organs were used for DNA adduct analysis. The 
tissue-specific expression of human SULT1A1/2 proteins in 
hSULT1A1/2 mice was qualitatively similar after treatment 
with AAI and AAII (Fig. 4a). No expression of human 
SULT1A1/2 protein (or a protein that could be confounded 
with human SULT1A1/2) was detected in WT mice under 
the experimental conditions used. No induction of human 
SULT1A1/2 proteins was found after AAI or AAII treat-
ment relative to control (vehicle-treated) mice. Relatively 
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high expression of hSULT1A1/2 proteins was observed in 
kidney, liver and lung; expression was lower in colon, small 
intestine and glandular stomach.
Strong expression of murine Nqo1 protein was observed 
in colon, small intestine, glandular stomach and kidney 
(Fig. 4a). Interestingly, the strongest expression of Nqo1 
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Fig. 2  Total DNA adduct levels measured by the nuclease P1 enrich-
ment version of the 32P-postlabelling method in various organs of WT 
and hSULT1A1/2 mice after exposure to a single oral dose of 50 mg/
kg body weight AAI (a) or AAII (b). Values are the mean ± SD 
(n = 4 animals). Statistical analysis was performed by Student’s 
t test; no significant differences were observed between WT and 
hSULT1A1/2 mice. Inserts Autoradiograms of DNA adducts, meas-
ured by 32P-postlabelling, in kidney tissue of hSULT1A1/2 mice. 
These profiles are representative of adduct pattern obtained with 
DNA from other mouse tissues including bladder, liver, lung, fores-
tomach, glandular stomach, small intestine and colon, and those in 
WT mice. The origin (OR) on the TLC plate, at the bottom left-hand 
corners, was cut off before exposure. 7-(deoxyadenosin-N6-yl)-aris-
tolactam I (dA-AAI); 7-(deoxyguanosin-N2-yl)-aristolactam I (dG-
AAI); 7-(deoxyadenosin-N6-yl)-aristolactam II (dA-AAII); 7-(deoxy-
guanosin-N2-yl)-aristolactam II (dG-AAII)
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was observed in glandular stomach, even though it had the 
weakest expression of human SULT1A1/2. Overall, the tis-
sue distribution of the Nqo1 protein expression was similar 
in WT and hSULT1A1/2 mice, except for glandular stom-
ach where expression levels were more variable (Fig. 4a). 
In comparison Nqo1 protein levels were relatively low in 
liver and lung and hardly visible on the blots comparing all 
tissues (Fig. 4a). Therefore, Nqo1 expression levels in kid-
ney, liver and lung were reanalysed in separate blots using 
a longer film exposure time. As shown in Fig. 4b, Nqo1 
expression was now clearly detectable in those tissues. 
Liver and kidney Nqo1 was induced by AAI and AAII in 
both WT and hSULT1A1/2 mice, whereas this effect was 
not seen in lung (Fig. 4b).
DNA adduct formation by AAI in vitro and enzyme 
activity in renal and hepatic cytosolic fractions isolated 
from WT and hSULT1A1/2 mice treated with AAI 
and AAII
In a second set of experiments to investigate the potential 
role of human SULT1A1/2 on the metabolic activation 
of AAI, we incubated renal or hepatic cytosolic fractions 
from WT and hSULT1A1/2 mice in vitro with DNA and 
AAI to determine AAI-DNA adduct formation by 32P-post-
labelling (Fig. 5). Cytosolic incubations were conducted 
in the presence and absence of PAPS but all contained 
NADPH as a cofactor. In the absence of PAPS, NADPH-
dependent DNA adduct formation of AAI in cytosols was 
used as a measure of AAI bioactivation by murine Nqo1. 
Subsequently in the presence of PAPS, any potential alter-
ations in AAI-DNA adduct levels should be attributable 
to AAI bioactivation by murine Sult1a1/2 in WT mice or 
human SULT1A1/2 in hSULT1A1/2 mice. Renal (Fig. 5; 
upper panels) and hepatic (Fig. 5; lower panels) cytosols 
were capable of bioactivating AAI to form DNA adducts, 
generating the same pattern of AAI-DNA adducts as found 
in vivo (Fig. 5, inserts). In both renal and hepatic cyto-
solic fractions of untreated WT and hSULT1A1/2 mice no 
difference in AAI-DNA adduct formation was observed 
after the addition of PAPS (Fig. 5), indicating that neither 
murine nor human SULTs contribute to AAI bioactivation. 
This conclusion is in line with the observation that Nqo1 
enzyme activity in renal and hepatic cytosolic fractions 
was similar for both genotypes (Fig. 6a, c), suggesting 
that AAI-DNA adduct formation in vitro is predominantly 
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Fig. 3  Total DNA adduct levels measured in various organs of WT 
and hSULT1A1/2 mice after exposure to a single i.p. dose of 2 mg/
kg body weight 3-NBA. DNA adduct formation was determined by 
the butanol-enrichment version of the 32P-postlabelling method. Val-
ues are the mean ± SD (n = 3 animals). F, fold difference in DNA 
binding relative to WT mice. Statistical analysis was performed 
by Student’s t test (*P < 0.05, **P < 0.01, ***P < 0.001; different 
from WT mice). Insert Autoradiogram of DNA adducts, measured by 
32P-postlabelling, in kidney tissue of hSULT1A1/2 mice. These pro-
files are representative of adduct pattern obtained with DNA from 
other mouse tissues including bladder, liver, lung, forestomach, glan-
dular stomach, small intestine and colon, and those in WT mice. The 
origin (OR) on the TLC plate, at the bottom left-hand corners, was 
cut off before exposure. Spot 1, 2-(2′-deoxyadenosin-N6-yl)-3-am-
inobenzanthrone (dA-N6-3-ABA); spot 2, as-yet-uncharacterised 
deoxyadenosine adduct; spot 3, 2-(2′-deoxyguanosin-N2-yl)-3-amin-
obenzanthrone (dG-N2-3-ABA); and spot 4, N-(2′-deoxyguanosin-8-
yl)-3-aminobenzanthrone (dG-C8-N-3-ABA)
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catalysed by Nqo1. In contrast, the sulfotransferase 
activities in renal and hepatic cytosols, measured colori-
metrically as sulfo-transfer from p-nitrophenol sulfate to 
2-naphthol, were manifold higher in hSULT1A1/2 mice 
compared to WT mice (Fig. 6b, d). As no difference in 
AAI-DNA adduct formation was observed in the presence 
of PAPS, despite massive differences in sulfotransferase 
activities in cytosolic fractions, these results confirm the 
conclusion that SULTs do not contribute to the metabolic 
activation of AAI (i.e. AAI-DNA adduct formation; Fig. 5) 
under these experimental conditions. 
Treatment of mice with AAI and AAII led to an induc-
tion of Nqo1 activity in both kidney and liver (Fig. 6a, c). For 
example, in WT kidney induction of Nqo1 activity was found 
both after AAI and AAII treatment whereas in liver only AAII 
was able to induce Nqo1 activity. Induction of sulfotrans-
ferase activity was also observed in both kidney and liver 
after AAI and AAII treatment; the pattern of induction was 
dependent on the mouse line (i.e. WT or hSULT1A1/2 mice) 
and compound used (i.e. AAI or AAII) (Fig. 6b, d). In incu-
bations using cytosolic fractions isolated from AAI- or AAII-
treated mice AAI-DNA adduct formation was significantly 
increased under certain experimental conditions relative to 
cytosolic incubations from untreated animals (Fig. 5). How-
ever, it is noteworthy that the increases in AAI-DNA adduct 
levels were often relatively small. Under certain experimental 
conditions AAI-DNA adduct levels observed in vitro seem to 
correlate with Nqo1 activity (compare Fig. 6a, c). Whereas 
in renal cytosols isolated from AAI- and AAII-treated mice 
increased AAI-DNA adduct levels seem to be associated with 
enhanced Nqo1 activity, these associations were less clear in 
hepatic cytosols isolated from AAI- and AAII-treated mice. 
Although both AAI and AAII were capable of inducing sul-
fotransferase activity in treated animals (Fig. 6b, d), no clear 
associations can be made to the observed AAI-DNA adduct 
levels in vitro in cytosolic incubations (compare Fig. 5). For 
example, given the strong differences in sulfotransferase 
activities in hepatic cytosols between WT and hSULT1A1/2 
mice in both control (vehicle-treated) and AAI-/AAII-treated 
animals, these differences are not observed in AAI-DNA 
adduct formation in vitro in the same cytosolic sample. Thus, 
it seems unlikely that sulfotransferase detected in the transfer 
assay make any major contribution to AAI bioactivation lead-
ing to DNA adduct formation in vitro.
Fig. 4  a Western blot analysis 
of human SULT1A1/2 and 
murine Nqo1 protein expression 
in whole tissue lysates isolated 
from WT and hSULT1A1/2 
mice after exposure to a single 
oral dose of 50 mg/kg body 
weight AAI or AAII. b Western 
blot analysis of murine Nqo1 
protein expression in whole 
tissue lysates isolated from 
the kidney, liver and lung of 
WT and hSULT1A1/2 mice 
after exposure to AAI or AAII. 
Gapdh was used as loading 
control and representative blots 
are shown. CO colon, SI small 
intestine, GS glandular stomach, 
KI kidney, LI liver, LU lung, 
SPL spleen. Representative 
images of the Western blotting 
are shown, and at least duplicate 
analysis was performed from 
independent experiments
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DNA adduct formation in WT versus Sult1a1(−/−) or 
Sult1d1(−/−) mice treated with AAI and AAII
We next studied the role of murine Sults on metabolic 
activation of AAI and AAII in vivo. AAI-/AAII-DNA 
adduct formation was determined by 32P-postlabelling 
in kidney, liver and small intestine of WT, Sult1a1(−/−) 
and Sult1d1(−/−) mice treated with a single oral dose 
of 50 mg/kg body weight AAI or AAII for 24 h. Besides 
Sult1a1 we also studied the potential influence of Sult1d1 
as this isoenzyme is also highly expressed in kidney 
(Alnouti and Klaassen 2006), the target organ of AA (geno)
toxicity. The DNA adduct pattern induced by AAI and 
AAII in WT, Sult1a1(−/−) and Sult1d1(−/−) mice was the 
same as that found in hSULT1A1/2 mice (Fig. 7, inserts).
Total DNA adduct levels after AAI and AAII treatment 
ranged from 25 to 800 adducts per 108 nucleotides (Fig. 7). 
Highest DNA binding was observed in the kidney after both 
AAI and AAII exposure. It should be noted that the treat-
ment of hSULT1A1/2 (compare Fig. 2) and knockout animals 
(Fig. 7) with AAI and AAII was done on separate occasions 
and that DNA adduct analyses for both treatment sets were 
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Fig. 5  Total AAI-DNA adducts, as measured by the nuclease 
P1-enrichment version of the 32P-postlabelling method, formed 
ex vivo in renal (a, b) and hepatic cytosols (c, d) isolated from 
untreated, AAI- or AAII-pretreated WT and hSULT1A1/2 mice incu-
bated with AAI and DNA in the absence (a and c) or presence of 
PAPS (b, d). Values are the mean ± range (n = 4; duplicate incuba-
tions and each sample was determined by two independent 32P-post-
labelling analyses). Statistical analysis was performed by two-way 
ANOVA followed by Tukey’s multiple comparison test (*P < 0.05, 
**P < 0.01, ***P < 0.001—different from control WT mice; 
#P < 0.05, ###P < 0.001—different from control hSULT1A1/2 mice; 
§§P < 0.01—different from incubation without PAPS). Inserts Repre-
sentative autoradiograms of DNA adducts, measured by 32P-postla-
belling, in AAI incubations with renal and hepatic cytosols. The ori-
gin (OR) on the TLC plate, at the bottom left-hand corners, was cut 
off before exposure. 7-(deoxyadenosine-N6-yl)-aristolactam I (dA-
AAI); 7-(deoxyguanosin-N2-yl)-aristolactam I (dG-AAI); 7-(deoxy-
adenosine-N6-yl)-aristolactam II (dA-AAII); 7-(deoxyguanosin-
N2-yl)-aristolactam II (dG-AAII)
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also done separately. These are possible reasons to explain 
the differences in DNA adduct levels observed in WT ani-
mals between sample sets; in AAI-treated kidney samples the 
difference is more pronounced than in AAII-treated kidney 
samples. In kidney knockout of Sult1a1 or Sult1d1 had no 
impact on AAI- or AAII-DNA adduct formation (Fig. 7a, d). 
Similarly, no differences in DNA adduct formation between 
mouse lines were found in liver (Fig. 7b, e) and small intes-
tine (Fig. 7c, f), except for AAI-treated Sult1d1(−/−) mice 
where DNA binding was ~twofold higher in liver relative to 
WT. Collectively, these results demonstrate that in kidney 
murine Sults (i.e. Sult1a1 or Sult1d1) do not contribute to 
AA genotoxicity (i.e. DNA adduct formation) in vivo.
DNA adduct formation by AAI and 3‑NBA in vitro 
and enzyme activity in renal and hepatic cytosolic 
fractions isolated from WT, Sult1a1(−/−) or 
Sult1d1(−/−) mice treated with AAI and AAII
Hepatic and renal cytosols isolated from AAI-/AAII-pre-
treated mice of all lines were incubated with AAI in the 
presence of DNA and the enzymatic cofactors NADPH 
and PAPS. We anticipated that any involvement of Sults 
in AAI bioactivation would result in diminished AAI-
DNA adduct formation in incubations using cytosolic frac-
tions from Sult-knockout mouse lines. Renal (Fig. 8a) and 
hepatic (Fig. 8b) cytosols were capable of bioactivating 
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Fig. 6  Measurement of Nqo1 (a, c) and sulfotransferase (b, d) 
enzyme activity in cytosolic fractions of the kidneys (upper panels) 
and livers (lower panels) from untreated, AAI- or AAII-treated WT and 
hSULT1A1/2 mice. Nqo1 enzyme activity was determined using mena-
dione and cytochrome c as substrate and expressed as nmol cytochrome 
c/min/mg protein. Sulfotransferase enzyme activity was determined 
using a colorimetric assay with p-nitrophenol sulfate as sulfo-donor 
and is expressed as nmol p-nitrophenol/min/mg protein. Values are 
the mean ± SD of three determinations. Statistical analysis was per-
formed by two-way ANOVA followed by Tukey’s multiple comparison 
test (*P < 0.05, **P < 0.01, ***P < 0.001—different from control WT 
mice; ###P < 0.001—different from control hSULT1A1/2 mice)
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AAI to form DNA adducts, generating the same pattern of 
AAI-DNA adducts formed in vivo (Fig. 8, inserts). With 
both renal and hepatic cytosolic fractions of untreated 
WT, Sult1a1(−/−) and Sult1d1(−/−) mice no difference 
in AAI-DNA adduct formation was observed in the pres-
ence of PAPS (Fig. 8), indicating that neither Sult1a1 nor 
Sult1d1 contributes to AAI bioactivation. This conclusion 
was in line with the observation that Nqo1 activity in renal 
and hepatic cytosolic fractions was similar for all three 
genotypes (Fig. 9), suggesting that AAI-DNA adduct for-
mation in vitro is predominantly catalysed by Nqo1. In 
contrast, when hepatic cytosols isolated from the same 
mouse lines were incubated with 3-NBA in the presence 
of DNA, NADPH and PAPS, 3-NBA-induced DNA adduct 
levels were diminished by ~60 % in Sult1a1(−/−) cyto-
solic incubations relative to WT (Fig. 10b). These find-
ings confirmed previous in vitro studies on the important 
role of SULT1A1 in 3-NBA genotoxicity (Arlt et al. 2001, 
2003, 2005). The contribution of murine Sults in the bio-
activation of 3-NBA was also demonstrated by the fact 
that 3-NBA-DNA adduct formation was up to ~eightfold 
higher in incubations in the presence of PAPS compared 
to incubations without PAPS (Fig. 10). The pattern of 
3-NBA-DNA adducts generated in vitro was the same as 
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Fig. 7  Total DNA adduct levels measured by the nuclease P1 
enrichment version of the 32P-postlabelling method in kidney (a, 
d), liver (b, e) and small intestine (c, f) of WT, Sult1a1(−/−) and 
Sult1d1(−/−) mice after exposure to a single oral dose of 50 mg/
kg body weight AAI (a–c) or AAII (d–f). Values are the mean ± SD 
(n = 4 animals). F, fold difference in DNA binding relative to WT 
mice. Statistical analysis was performed by one-way ANOVA fol-
lowed by Tukey’s multiple comparison test (*P < 0.05—different 
from WT mice). Inserts Autoradiograms of DNA adducts, measured 
by 32P-postlabelling, in kidney tissue of Sult1a1(−/−) mice. These 
profiles are representative of adduct pattern obtained with DNA from 
liver and small intestine, and those in WT and Sult1d1(−/−) mice. 
The origin (OR) on the TLC plate, at the bottom left-hand corners, 
was cut off before exposure. 7-(deoxyadenosin-N6-yl)-aristolactam 
I (dA-AAI); 7-(deoxyguanosin-N2-yl)-aristolactam I (dG-AAI); 
7-(deoxyadenosin-N6-yl)-aristolactam II (dA-AAII); 7-(deoxyguano-
sin-N2-yl)-aristolactam II (dG-AAII)
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that found in vivo (Fig. 10, insert). As shown in Fig. 10b 
disruption of Sult1d1 had no impact on 3-NBA-DNA 
adduct formation relative to WT.
The results obtained in incubations using cytosolic frac-
tions isolated from AAI- or AAII-pretreated mice were 
more complex. As shown in Fig. 9 treatment of mice with 
AAI and AAII led to the induction of Nqo1 activity (com-
pare also Fig. 6a, c). However, increased Nqo1 activity 
did not always correlate with the AAI-DNA adduct levels 
observed in in vitro incubations (compare Figs. 8 and 9). In 
other cytosolic incubations such as Sult1a1(−/−)-AAI and 
Sult1d1(−/−)-AAII (Fig. 9b) AAI-DNA adduct formation 
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Fig. 8  Total AAI-DNA adduct levels, as measured by the nucle-
ase P1-enrichment version of the 32P-postlabelling method, formed 
ex vivo in renal (a) and hepatic cytosols (b) isolated from untreated, 
AAI- or AAII-pretreated WT, Sult1a1(−/−) and Sult1d1(−/−) mice 
incubated with AAI and DNA in the presence of PAPS. Values are 
the mean ± range (n = 4 analyses; duplicate incubations and each 
sample was determined by two independent 32P-postlabelling analy-
ses). Statistical analysis was performed by two-way ANOVA fol-
lowed by Tukey’s multiple comparison test (*P < 0.05, **P < 0.01, 
***P < 0.001—different from control WT mice; ##P < 0.01, 
###P < 0.001—different from control Sult1d1(−/−) mice). Inserts 
Representative autoradiograms of DNA adducts, measured by 
32P-postlabelling, in AAI incubations with renal and hepatic cytosols. 
The origin (OR) on the TLC plate, at the bottom left-hand corners, 
was cut off before exposure. 7-(deoxyadenosine-N6-yl-aristolactam 
I (dA-AAI); 7-(deoxyguanosin-N2-yl-aristolactam I (dG-AAI); 
7-(deoxyadenosine-N6-yl-aristolactam II (dA-AAII); 7-(deoxyguano-
sin-N2-yl-aristolactam II (dG-AAII)
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was actually lower compared to cytosolic incubations from 
control (vehicle-treated) mice of the same genotype. How-
ever, observed changes were relatively small, so it is diffi-
cult to draw any solid conclusions from these observations.
Discussion
A powerful tool of elucidating the activation pathway of 
chemical carcinogens is to analyse their ability to produce 
covalent DNA adducts and to determine what factors either 
enhance or inhibit adduct formation (Phillips 2013). This 
approach has been successfully used by Stiborova and 
co-workers to assess the bioactivation of AA (Arlt et al. 
2015a; Stiborova et al. 2013, 2014a) and was therefore also 
employed in the present study. For the detection of DNA 
adducts we used the 32P-postlabelling method because the 
chemical structures of AA-DNA adducts observed in this 
assay have been identified. As for other nitroaromatics 
(Arlt 2005), nitroreduction is the major activation pathway 
of AAI and AAII that is catalysed by a number of cyto-
solic and microsomal enzymes, cytosolic NQO1 being the 
most efficient nitroreductase (Stiborova et al. 2001b, 2002, 
2003). Following activation by NQO1 both AAI and AAII 
produce specific DNA adducts identical to those found in 
humans (Nortier et al. 2000; Schmeiser et al. 1996, 2012, 
2014), confirming that nitroreduction is the crucial step in 
the bioactivation of AA (Martinek et al. 2011; Stiborova 
et al. 2011).
Recently we reported that, in contrast to NQO1, human 
cytosolic phase II enzymes such as N,O-acetyltransferases 
(NATs) and SULTs do not play a role in AAI activation 
in cell-free in vitro systems (Stiborova et al. 2011). Nei-
ther native enzymes present in human cytosol nor human 
recombinant sulfotransferase enhanced AAI-DNA adduct 
levels in vitro. Likewise, cofactors of NAT and SULT 
enzymes, acetyl-CoA and PAPS, respectively, did not stim-
ulate the activation of AAI in human cytosolic samples rich 
Fig. 9  Nqo1 enzyme activ-
ity in cytosolic fractions of 
the kidneys (a) and livers (b) 
from untreated, AAI- or AAII-
treated WT, Sult1a1(−/−) and 
Sult1d1(−/−) using menadione 
and cytochrome c as substrate. 
Values are the mean ± SD of 
three determinations; Nqo1 
enzyme activity is expressed 
as nmol cytochrome c/min/mg 
protein. Statistical analysis was 
performed by two-way ANOVA 
followed by Tukey’s multiple 
comparison test (*P < 0.05, 
**P < 0.01, ***P < 0.001—dif-
ferent from control WT mice; 
§§P < 0.01, §§§P < 0.001—
different from control 
Sult1a1(−/−) mice; ##P < 0.01, 
###P < 0.001—different from 
control Sult1d1(−/−) mice, 
respectively)
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in these enzymes. These findings fully correspond to results 
obtained in our previous study utilising cytosolic samples 
of several human donors to identify the participation of 
cytosolic enzymes in AAI activation (Stiborova et al. 2003).
Conjugation reactions catalysed by phase II enzymes 
like SULTs have been shown to be involved in the meta-
bolic activation of many carcinogenic nitroaromatics and 
aromatic amines (Arlt et al. 2002b, 2003, 2005; Dob-
bernack et al. 2011; Glatt and Meinl 2004; Glatt et al. 
2016; Krais et al. 2016b). Hydroxylamine metabolites of 
nitroaromatics generally acquire increased reactivity upon 
sulfo-conjugation. We have shown in previous studies that 
the genotoxicity (i.e. DNA adduct formation) of another 
nitroaromatic, namely 3-NBA, is strongly influenced by 
human SULT1A1 and SULT1A2 (Arlt et al. 2002b, 2003, 
2005). As expected treatment of hSULT1A1/2 mice with 
3-NBA resulted in higher 3-NBA-DNA adduct forma-
tion in several organs compared to WT mice, demonstrat-
ing that the expression of human SULT1A1/2 increases 
the activation of 3-NBA in vivo. These results confirm the 
suitability of the employed mouse model to study the role 
of human SULT1A enzymes in the metabolism of environ-
mental toxins. Other studies have used this mouse line to 
demonstrate the involvement of human SULT1A1/2 in the 
activation of the food genotoxicants 2-amino-1-methyl-
6-phenylimidazo[4,5-b]pyridine (PhIP) (Dobbernack et al. 
2011), furfuryl alcohol (Sachse et al. 2014), 1-methylpyr-
ene (Bendadani et al. 2014b) and methyleugenol (Her-
rmann et al. 2014).
In the case of AA, the N-hydroxyaristolactams may be 
further activated by O-acetylation or O-sulfo-conjugation 
to reactive esters capable of forming the same electrophilic 
species (aristolactam-nitrenium ions) as by nitroreductases 
and eventually the same AA-DNA adducts. However, such 
aristolactam-N-acetic acid esters or aristolactam-N-sulfuric 
acid esters have not yet been identified in in vivo studies 
on the metabolism of AA. When comparing DNA adduct 
formation of AAI and AAII between hSULT1A1/2 and WT 
mice, we found no significant differences in adduct levels 
or adduct patterns in several organs examined. Expression 
of human SULT1A1/2 proteins detected by immunoblot-
ting was found only in the hSULT1A1/2 mice and not in 
WT mice. We also showed that the sulfotransferase activ-
ity in kidney and liver, the major organs involved in AA 
biotransformation, was many times higher in hSULT1A1/2 
than WT mice but the increase in sulfotransferase activity 
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Fig. 10  Total 3-NBA-DNA adduct levels, as measured by the 
butanol-enrichment version of the 32P-postlabelling method, formed 
in vitro in hepatic cytosols isolated from WT, Sult1a1(−/−) and 
Sult1d1(−/−) mice incubated with 3-NBA and DNA in the absence 
(a) or presence of PAPS (b). Values are the mean ± range (n = 4 
analyses; duplicate incubations and each sample was determined by 
two independent 32P-postlabelling analyses). Statistical analysis was 
performed by two-way ANOVA followed by Tukey’s multiple com-
parison test (***P < 0.001—different from WT mice; §§§P < 0.001—
different from incubation without PAPS). Insert Representative 
autoradiogram of DNA adducts, measured by 32P-postlabelling, in 
AAI incubations with hepatic cytosols. The origin (OR) on the TLC 
plate, at the bottom left-hand corners, was cut off before exposure. 
Spot 1, 2-(2′-deoxyadenosin-N6-yl)-3-aminobenzanthrone (dA-N6-
3-ABA); spot 2, as-yet uncharacterised deoxyadenosine adduct; 
spot 3, 2-(2′-deoxyguanosin-N2-yl)-3-aminobenzanthrone (dG-N2-3-
ABA); and spot 4, N-(2′-deoxyguanosin-8-yl)-3-aminobenzanthrone 
(dG-C8-N-3-ABA)
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was not reflected in DNA adduct formation in these tissues 
as no differences were observed. These findings indicate 
that expression of human SULT1A1/2 does not contribute 
to the bioactivation of AAs in vivo.
Mouse models and cells derived from mice are often 
used to study experimental AAN and mechanisms related 
to AA carcinogenesis (Arlt et al. 2011; Baudoux et al. 
2012; Krais et al. 2015; Nik-Zainal et al. 2015; Odell 
et al. 2013; Wang et al. 2012). Thus, it is also important 
to understand the role of murine Sults on AA bioactiva-
tion. Alongside the Sult1a1(−/−) mice we also included 
mice with a knockout of Sult1d1, an isoform that is pref-
erentially expressed in mouse kidney (Alnouti and Klaas-
sen 2006) and thus could contribute to the (geno)toxicity 
of AA in its target organ. In the tissues analysed adduct 
levels in Sult1a1(−/−) and Sult1d1(−/−) mice were 
similar to those in WT mice, except for AAI-treated liv-
ers of Sult1d1(−/−) mice where actually increased AAI-
DNA adduct formation was observed. Collectively, these 
findings indicate that murine Sult1a1 and Sult1d1 do not 
contribute to the metabolic activation of AA in vivo. In 
contrast, we recently showed that Sult1a-mediated bio-
activation of PhIP in the kidney depended on Trp53 sta-
tus in mice (Krais et al. 2016b) and other studies using 
the Sult1a1(−/−) and Sult1d1(−/−) mice mouse lines 
have demonstrated that expression of murine Sult1a1 and 
Sult1d1 can be a critical determinant in the genotoxicity 
of furfuryl alcohol (Sachse et al. 2014), methyleugenol 
(Herrmann et al. 2014) and 1-hydroxymethylpyrene (Ben-
dadani et al. 2014a).
It should be mentioned that studies using in vitro sys-
tems (e.g. utilising recombinant human enzymes) to eluci-
date the role of human SULT1A1 in the bioactivation of AA 
have generated conflicting results (Martinek et al. 2011; 
Meinl et al. 2006; Sidorenko et al. 2014; Stiborova et al. 
2011). For instance, whereas overexpression of human 
recombinant SULT1A1 in mammalian cells increased the 
genotoxicity (i.e. mutagenicity) of AA (Meinl et al. 2006), 
human recombinant SULT1A1 did not increase AA geno-
toxicity (i.e. DNA adduct formation) in a cell-free system 
(Stiborova et al. 2011). Although useful, these models 
have limitations, including the challenge of predicting the 
in vivo situation from reductionist in vitro results. In con-
trast, in vivo mouse models (i.e. hSULT1A1/2 mice) take 
additional factors besides enzyme expression into account, 
such a route-of-administration, absorption, renal clear-
ance and tissue-specific expression of XMEs. They also 
consider factors such as induction and/or inhibition of 
XMEs, as well as the presence of a variety of phase I and 
II enzymes, as critical determinants for the formation of 
reactive AA metabolites in vivo capable of forming DNA 
adducts. Several studies have shown that XMEs can behave 
differently in vitro and in vivo (Arlt et al. 2008, 2012; Krais 
et al. 2016a; Wohak et al. 2016). For example, some studies 
have revealed a paradox whereby CYP enzymes (particu-
larly CYP1A1) appear to be more important for detoxifica-
tion of benzo[a]pyrene in vivo, despite being involved in its 
metabolic activation in vitro (Arlt et al. 2008; Nebert et al. 
2013).
Using ab initio calculations and molecular model-
ling have shown that the reaction free energy of dissocia-
tion of N-hydroxyaristolactam I is lower than that for N–
OH-3-ABA (Stiborova et al. 2011, 2014b), the reactive 
intermediate of 3-NBA, the latter being used as a positive 
control in the present study. Hence, N-hydroxyaristolac-
tam I decomposes spontaneously under the same condi-
tions. Consequently, if the dissociation of the N–O bond 
in N-hydroxyaristolactam I (or its precursor, the open-ring 
hydroxylamine) is relatively fast, it is not the rate-limiting 
step in AAI-DNA adduct formation and any conjuga-
tion reaction (e.g. sulfation) would not make dissociation 
faster (i.e. would not lead to enhanced AAI-DNA adduct 
levels). These results indicate that the overall rate-control-
ling step during the reductive activation of AAI is not the 
enzymatic conjugation followed by spontaneous forma-
tion of the nitrenium/carbonium ion capable of reacting 
the DNA, but rather the initial nitroreduction mediated by 
NQO1 (Stiborova et al. 2011, 2014b). It should be noted 
that in the present study we did not treat the hSULT1A1/2 
mice with N-hydroxyaristolactams as these AA metabolites 
were not available to us. Although it might be useful to treat 
hSULT1A1/2 mice with N-hydroxyaristolactams in future 
investigations, it is important to emphasise that humans 
are exposed to the natural mixture AA containing AAI and 
AAII and not N-hydroxyaristolactams 1 and 2. Interest-
ingly, in vitro experiments with enzyme systems using AAI 
in the presence of NQO1, instead of N-hydroxyaristolactam 
I, showed that AAI-DNA adduct formation only increased 
after the addition of human SULT1B1 but not after the addi-
tion of SULT1A1 or SULT1A2 (Sidorenko et al. 2014), sug-
gesting that human SULT1B1 may contribute to bioactiva-
tion of AA. Likewise, human SULT1B1 expressed in the 
target strain Salmonella typhimurium TA1538 enhanced the 
mutagenicity of AA, although somewhat less than expres-
sion of human SULT1A1 (Meinl et al. 2006). However, 
human SULT1B1 is primarily expressed in gut (Teubner 
et al. 2007); its expression in kidney is minimal (Meinl et al. 
2006). Further studies are required to establish if human 
SULT1B1 contributes to the metabolic activation of AA 
in vivo.
In the present study, we investigated the contribution of 
the phase II enzyme SULT1A1 to the bioactivation of AAI 
and AAII in vivo using a transgenic mouse line carrying 
the functional human SULT1A1-SULT1A2 gene cluster as 
well as Sult1a1(−/−) and Sult1d1(−/−) knockout mouse 
lines. In summary, our results indicate that conjugation by 
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sulfation catalysed by SULT1A1/Sult1a1 does not play a 
role in the bioactivation of AAI and AAII in mice, whereas 
it is important in the activation of 3-NBA.
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